DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20222726
Published: 2022-10-27

Management of skin and soft-tissue infections and acne with topical nadifloxacin: a comprehensive review

Snehal Muchhala, Rashmi Sarkar, Koushik Lahiri, Rajendra D. Kharkar, Rahul Rathod

Abstract


Skin and soft tissue infections (SSTIs) and acne are multi-factorial skin conditions that involve microbial invasion of the skin and underlying soft tissues; though, both have different pathogenesis. Most of these infections are caused by bacteria, affecting all age groups. Early diagnosis and appropriate antimicrobial therapy remain the cornerstone of management of SSTIs and acne. Over the years, an increase in antibiotic resistance has been reported with mupirocin and fusidic acid that makes the management of SSTIs and acne increasingly challenging. Further, these antibiotics are unable to penetrate biofilms and show their action on the microorganisms embedded deep in the polymeric matrix. In this review, we have discussed the current evidence on the efficacy and safety profile of nadifloxacin compared to other currently available antimicrobial agents. An extensive search was performed through PubMed and Medline using relevant key words. This article has highlighted nadifloxacin’s broad antimicrobial spectrum, unique dual mechanism of action, distinct characteristics like ability to retain efficacy in acidic pH, low antibiotic resistance and superior action against biofilms. This review concludes that nadifloxacin, could be a potential empirical therapy in the management of SSTIs and acne.


Keywords


Acne vulgaris, SSTI, Nadifloxacin, Antibiotic resistance, Biofilm, Topical

Full Text:

PDF

References


Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Raşa K, et al. 2018 WSES/SIS-E consensus conference: Recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13(1):1-24.

Nathwani D, Dryden M, Garau J. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int J Antimicrob Agents. 2016;48(2):127-36.

Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, et al. Comparison of staphylococcus aureus from skin and soft-tissue infections in us emergency Department patients, 2004 and 2008. Clin Infect Dis. 2011;53(2):144-9.

Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173-84.

Kaye KS, Petty LA, Shorr AF, Zilberberg MD. Current epidemiology, etiology, and burden of acute skin infections in the United States. Clin Infect Dis. 2019;68(3):S193-9.

Abhilash KPP, Varghese S. Profile and outcome of patients presenting with skin and soft-tissue infections to the emergency department. Curr Med Issues. 2019;17(2):30.

Vasani, Medhekar SV. Topical 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections of the skin. Indian J Drugs Dermatol. 2015;1(1):16.

Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012;86(8):734-40.

Abbafati C, Machado DB, Cislaghi B. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.

Bhagwat SS, Nandanwar M, Kansagara A, et al. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: Review of current evidence. Drug Des Devel Ther. 2019;13:4351-65.

Narayanan V, Motlekar S, Kadhe G, Bhagat S. Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies. Dermatol Ther (Heidelb). 2014;4(2):233-48.

Silverberg B. A Structured Approach to Skin and Soft Tissue Infections (SSTIs) in an Ambulatory Setting. Clin Pract. 2021;11(1):65-74.

Thurlow LR, Joshi GS, Richardson AR. Peroxisome Proliferator-Activated Receptor γ Is Essential for the Resolution of Staphylococcus aureus Skin Infect. Cell Host Microbe. 2018;24(2):261-70.

Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959-74.

Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29:1-7.

Tan JKL, Stein Gold LF, Alexis AF, Harper JC. Current concepts in acne pathogenesis: Pathways to inflammation. Semin Cutan Med Surg. 2018;37(3 S):S60-2.

Stevens D, Bisno A, Chambers H, Dellinger E, Goldstein E, Gorbach S. Stevens DL - 2014.pdf. Clin Infect Dis. 2014;59(2):e10-52.

Patankar S. Changing trends in abscess management. Med J Dr DY Patil Univ. 2014;7(6):747.

Kraft J, Freiman A. Management of acne. Cmaj. 2011;183(7).

Shah BJ, Sumathy TK, Dhurat RS. Efficacy and tolerability of topical fixed combination of nadifloxacin 1% and adapalene 0.1% in the treatment of mild to moderate acne vulgaris in indian patients: A multicenter, open-labelled, prospective study. Indian J Dermatol. 2014;59(4):385-9.

Barbieri JS, Spaccarelli N, Margolis DJ, James WD. Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538-49.

Wagner N, Benkali K, Alió Sáenz A, Poncet M, Graeber M. Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid. J Clin Pharmacol. 2020.

Bakthavatchalam YD, Rao SV, Isaac B. infections. Indian J Med Microbiol. 2019;37:478-87.

Saxena D, Kaul G, Dasgupta A, Chopra S. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA. Drugs of Today. 2020;56(9):583-98.

Choudhury S, Chatterjee S, Sarkar DK, Dutta RN. Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol. 2011;43(6):628-31.

Dubois J, Dubois M. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019;68(12):1716-22.

Jung JY, Kwon HH, Yeom KB, Yoon MY, Suh DH. Clinical and histological evaluation of 1% nadi?oxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol. 2011;50(3):350-7.

Peng K-T, Huang T-Y, Chiang Y-C. Comparison of Methicillin-Resistant Staphylococcus aureus Isolates from Cellulitis and from Osteomyelitis in a Taiwan Hospital, 2016–2018. J Clin Med. 2019;8(6):816.

Hetem DJ, Bonten M. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013;85(4):249-56.

Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: Clinical implications and potential alternatives for the eradication of mrsa. J Antimicrob Chemother. 2015;70(10):2681-92.

Alba V, Urban E, Angeles Dominguez M. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents. 2009;33(3):272-5.

Matsuzaki K, Omika K, Hasegawa M, Sato Y, Kobayashi I. Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections. Jpn J Antibiot. 2006;59(4):316-20.

Coenye T, Brackman G, Rigole P. Eradication of Propionibacterium acnes biofilms by plant extracts and putative identification of icariin, resveratrol and salidroside as active compounds. Phytomed. 2012;19(5):409-12.

Lister JL, Horswill AR. Staphylococcus aureus biofilms: Recent developments in biofilm dispersal. Front Cell Infect Microbiol. 2014;4:1-9.

Doǧan B, Bektöre B, Karabacak E, Özyurt M. Resistance status of antibiotics in Gram-positive bacteria isolated from acne lesions in Istanbul. Turkderm Deri Hast ve Frengi Ars. 2017;51(2):32-6.

Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy. 2004;50(4):196-201.

Wilhelm KP, Wilhelm D, Neumeister C, Zsolt I, Schwantes U. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. Clin Exp Dermatol. 2012;37(2):112-7.

Kaur J, Sehgal V, Gupta A, Singh S. A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. Int J Appl Basic Med Res. 2015;5(2):106-10.

Schöfer H, Göllner A, Kusche W, Schwantes U. Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I-II): Results of a non-interventional trial in 555 patients. J Appl Res. 2009;9(3):44-51.

Kimata H. Effect of nadifioxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur J Pediatr. 1999;158(11):949.